Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Completed × pralsetinib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Recruiting 3 Unknown 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Cyclophosphamide 736 Cisplatin 684 Gemcitabine 637 Bevacizumab 610 Carboplatin 601 Paclitaxel 599 Docetaxel 566 Radiotherapy 534 Fluorouracil 400 Oxaliplatin 384 Rituximab 368 Doxorubicin 356 Capecitabine 341 Filgrastim 333 Etoposide 327 Dexamethasone 310 Irinotecan 306 pembrolizumab 272 Leucovorin 271 Cetuximab 265 Cytarabine 241 Erlotinib Hydrochloride 231 Prednisone 225 Trastuzumab 224 Bortezomib 222 Vincristine 218 Nivolumab 218 Methotrexate 205 Pemetrexed 199 fludarabine phosphate 195

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04632992 2025-01-08

MyTACTIC

Genentech, Inc.

Phase 2 Completed

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡